NKG2D-IG fusion protein for cancer immunotherapy
AssigneeDana-Farber Cancer Institute, Inc.
InventorsGlenn Dranoff, Ryan Sullivan, Matthew Vanneman
Life of this patent
Estimating the term…
Abstract
Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
Claims14
A dimeric NKG2D-Fc chimera including two distinct NKG2D ligand binding sites, each NKG2D ligand binding site attached to an Fc fragment, wherein:
- each NKG2D ligand binding site comprises NKG2D or a ligand binding portion of NKG2D;
- and the Fc fragment comprises a fragment crystallizable region (Fc) of an immunoglobulin.
A composition comprising:
- a dimeric NKG2D-Fc chimera including two distinct NKG2D ligand binding sites, each NKG2D ligand binding site attached to an Fc fragment, wherein:
- each NKG2D ligand binding site comprises NKG2D or a ligand binding portion of NKG2D;
- and the Fc fragment comprises a fragment crystallizable region (Fc) of an immunoglobulin;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.